Dynavax Conference Call / Webcast Tomorrow on Topline Phase 3 Data and Q2 Financial Results
To join the Conference Call, please dial 1-877-280-7280. International callers can dial 1-707-287-9365. A telephonic replay of the discussion will be available 90 minutes after its conclusion and through
The webcast can be accessed on
HEPLISAV™ is an investigational adult hepatitis B vaccine. In an earlier completed pivotal Phase 3 trial, HEPLISAV demonstrated increased, rapid protection with fewer doses than current licensed vaccines.
Shari AnnesInvestor Relations 510-665-7211 Email Contact Jennifer LewVice President, Finance 510-665-7217 Email Contact
News Provided by Acquire Media